Delving into the Latest Updates on MB-102(Mustang Bio, Inc.) with Synapse

Overview

Basic Info

Drug Type

Universal CAR-T

Synonyms

Target

CD123

Mechanism

CD123 modulators(Interleukin-3 receptor subunit alpha modulators), T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Acute Biphenotypic LeukemiaAdult Acute Lymphocytic LeukemiaAdult Acute Myeloblastic Leukemia+ [4]

Inactive Indication-

Originator Organization

Mustang Bio, Inc.

Active Organization

Mustang Bio, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm that has returned after a period of improvement or has not responded to previous treatment. An immune cell is a type of blood cell that can recognize and kill abnormal cells in the body. The immune cell product will be made from patient or patient's donor (related or unrelated) blood cells. The immune cells are changed by inserting additional pieces of deoxyribonucleic acid (DNA) (genetic material) into the cell to make it recognize and kill cancer cells. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

Start Date15 Dec 2015

Sponsor / Collaborator

City of Hope National Medical Center

[+2]

100 Clinical Results associated with MB-102(Mustang Bio, Inc.)

Login to view more data

100 Translational Medicine associated with MB-102(Mustang Bio, Inc.)

Login to view more data

100 Patents (Medical) associated with MB-102(Mustang Bio, Inc.)

Login to view more data

10

Literatures (Medical) associated with MB-102(Mustang Bio, Inc.)

01 Jan 2024·Gastro Hep Advances

First-in-Human Assessment of Gut Permeability in Crohn’s Disease Patients Using Fluorophore Technology

Article

Author: Nix, B Darren ; Dorshow, Richard B ; Deepak, Parakkal ; Akuse, Sewuese E ; Zulfiqar, Maria ; Shieh, Jeng-Jong ; Newberry, Rodney D ; Johnson, James R ; Riley, I Rochelle ; Holtz, Lori R ; Ciorba, Matthew A ; Hall-Moore, Carla

Background and AimsThe dual sugar absorption test as a classic measure of human intestinal permeability has limited clinical utility due to lengthy and cumbersome urine collection, assay variability, and long turnaround. We aimed to determine if the orally administered fluorophore MB-102 (relmapirazin) (molecular weight [MW] = 372) compares to lactulose (L) (MW = 342) and rhamnose (R) (MW = 164)-based dual sugar absorption test as a measure of gut permeability in people with a spectrum of permeability including those with Crohn's disease (CD).MethodsWe performed a single-center, randomized, open-label, crossover study comparing orally administered MB-102 (1.5 or 3.0 mg/kg) to L (1000 mg) and R (200 mg). Adults with active small bowel CD on magnetic resonance enterography (cases) and healthy adults (controls) were randomized to receive either MB-102 or L and R on study day 1, and the other tracer 3 to 7 days later. Urine was collected at baseline and 1, 2, 4, 6, 8, 10, and 12 hours after tracer ingestion to calculate the cumulative urinary percent excretion of MB-102 and L and R.ResultsNine cases and 10 controls completed the study without serious adverse events. Urinary recovery of administered MB-102 correlated with recovery of lactulose (r-squared = 0.83) for all participants. MB-102 urine recovery was also tracked with the L:R ratio urine recovery (r-squared = 0.57). In controls, the percentages of L and MB-102 recovered were similar within a narrow range, unlike in CD patients.ConclusionThis first-in-human study of an orally administered fluorophore to quantify gastrointestinal permeability in adults with CD demonstrates that MB-102 is well tolerated, and its recovery in urine mirrors that of percent L and the L:R ratio.

01 Jul 2023·ASAIO Journal

Adsorption and Clearance of the Novel Fluorescent Tracer Agent MB-102 During Continuous Renal Replacement Therapy: In Vitro Results

Article

Author: Dorshow, Richard B. ; Riley, Ivan R. ; Jang, Soo M. ; Shieh, Jeng-Jong ; Mueller, Bruce A.

MB-102 is a novel fluorescent tracer agent that is exclusively removed from the body by glomerular filtration. This agent can be detected transdermally to provide a real-time measurement of glomerular filtration rate at the point-of-care and is currently in clinical studies for such. MB-102 clearance during continuous renal replacement therapy (CRRT) is unknown. Its plasma protein binding (~0%), molecular weight (~372 Da) and volume of distribution (15–20 L) suggest that it may be removed by renal replacement therapies. To determine the disposition of MB-102 during CRRT, an in vitro study assessing the transmembrane clearance (CLTM) and adsorptive clearance of MB-102 was conducted. A validated in vitro bovine blood continuous hemofiltration (HF) and continuous hemodialysis (HD) models were performed using two types of hemodiafilters to evaluate CLTM of MB-102. For HF, three different ultrafiltration rates were evaluated. For HD, four different dialysate flow rates were evaluated. Urea was used as a control. No MB-102 adsorption to the CRRT apparatus or either of hemodiafilters was observed. MB-102 is readily removed by HF and HD. Dialysate and ultrafiltrate flow rates directly influence MB-102 CLTM. Hence MB-102 CLTM should be measurable for critically ill patients receiving CRRT.

01 Jul 2023·ASAIO Journal

Transdermal Detection of MB-102 and Correlation to Meropenem Pharmacokinetics During Continuous Renal Replacement Therapy: In Vivo Results

Article

Author: Johnson, James R. ; Pino, Christopher J. ; Riley, I. Rochelle ; Johnston, Kimberly A. ; Tang, Peter ; Dorshow, Richard B. ; Rogers, Thomas E. ; Nolin, Thomas D. ; Shieh, Jeng-Jong ; Goldstein, Stuart L. ; Humes, H. David

Critically ill patients undergoing continuous renal replacement therapy (CRRT) have medical conditions requiring extensive pharmacotherapy. Continuous renal replacement therapy impacts drug disposition. Few data exist regarding drug dosing requirements with contemporary CRRT modalities and effluent rates. The practical limitations of pharmacokinetic studies requiring numerous plasma and effluent samples, and lack of generalizability of observations from specific CRRT prescriptions, highlight gaps in bedside assessment of CRRT drug elimination and individualized dosing needs. We employed a porcine model using transdermal fluorescence detection of the glomerular filtration rate fluorescent tracer agent MB-102, with the aim to assess the relationship between systemic exposure of MB-102 and meropenem during CRRT. Animals underwent bilateral nephrectomies and received intravenous bolus doses of MB-102 and meropenem. Once MB-102 equilibrated in the animal, CRRT was initiated. Continuous renal replacement therapy prescriptions comprised four combinations of blood pump (low versus high) and effluent (low versus high) flow rates. Changes in transdermal detected MB-102 clearance occurred immediately with a change in CRRT rates. Blood side meropenem clearance mirrored transdermal MB-102 clearance (r2: 0.95–0.97, p value all <0.001). We suggest transdermal MB-102 clearance provides real-time personalized assessment of drug elimination and could optimize prescription of drugs for critically ill patients requiring CRRT.

100 Deals associated with MB-102(Mustang Bio, Inc.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Biphenotypic Leukemia	Phase 1	US	Mustang Bio, Inc.	15 Dec 2015
Adult Acute Lymphocytic Leukemia	Phase 1	US	Mustang Bio, Inc.	15 Dec 2015
Adult Acute Myeloblastic Leukemia	Phase 1	US	Mustang Bio, Inc.	15 Dec 2015
Blastic Plasmacytoid Dendritic Cell Neoplasm	Phase 1	US	Mustang Bio, Inc.	15 Dec 2015
Refractory acute myeloid leukemia	Phase 1	US	Mustang Bio, Inc.	15 Dec 2015
Relapsing acute myeloid leukemia	Phase 1	US	Mustang Bio, Inc.	15 Dec 2015
Residual Neoplasm	Phase 1	US	Mustang Bio, Inc.	15 Dec 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02159495 (AACR2020) Manual	Phase 1	Acute Myeloid Leukemia \| Blastic Plasmacytoid Dendritic Cell Neoplasm	9	CD123CAR (AML)	(xydiwjkndw) = ilijzqvqtv yqnhzqrgtz (cyoujlnyvs ) View more	Positive	01 Apr 2020
				CD123CAR (BPDCN)	(ilnxpnnlhq) = yleesphxad pnhqqvaisp (jsifbqtakq )